One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin.

Authors

Daniel B Brown, Thomas Jefferson UniversityFollow
Carin F Gonsalves, Thomas Jefferson UniversityFollow
Charles J Yeo, Thomas Jefferson UniversityFollow
Agnes K Witkiewicz, Thomas Jefferson UniversityFollow
Brian I Carr, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

9-1-2010

Comments

This article is peer reviewed. It is published in Oncology Reports, 2010 Sep;24(3):767-9. ©Spandidos Publications

Abstract

While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.

Recommended Citation

Brown, Daniel B; Gonsalves, Carin F; Yeo, Charles J; Witkiewicz, Agnes K; and Carr, Brian I, "One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin." (2010). Department of Radiology Faculty Papers. Paper 23.
https://jdc.jefferson.edu/radiologyfp/23

PubMed ID

20664985